CLIMB BIO INC(简称:CLYM)正式声明,公司不应承担Alumis就其研发药物布多普鲁替格(Budoprutug)所追索的里程碑付款义务。这一立场凸显了双方在合作协议条款理解上的根本分歧。
目前,CLIMB BIO INC正全力推进布多普鲁替格的临床开发进程。公司强调,其所有财务义务均严格遵循既有合同约定,不存在Alumis所主张的付款责任。此次争议的解决将直接影响后续研发资源的配置与合作伙伴关系的走向。
CLIMB BIO INC(简称:CLYM)正式声明,公司不应承担Alumis就其研发药物布多普鲁替格(Budoprutug)所追索的里程碑付款义务。这一立场凸显了双方在合作协议条款理解上的根本分歧。
目前,CLIMB BIO INC正全力推进布多普鲁替格的临床开发进程。公司强调,其所有财务义务均严格遵循既有合同约定,不存在Alumis所主张的付款责任。此次争议的解决将直接影响后续研发资源的配置与合作伙伴关系的走向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.